As hospital-acquired infections rise and the widespread use of broad-spectrum antibiotics gives birth to dangerous new pathogens, a host of biotech start-ups are focusing their research on novel approaches to target bacteria resistance.
As hospital-acquired infections rise and the widespread use of broad-spectrum antibiotics gives birth to dangerous new pathogens, a host of biotech start-ups are focusing their research on novel approaches to target bacteria resistance.
